Horizon shells out $510M for access to gout med Krystexxa

Horizon ($HZNP) may have quit on its hostile pursuit of California's Depomed ($DEPO), but that doesn't mean it's quit on dealmaking altogether. On the contrary, on Friday it announced an all-cash, $510 million deal for Crealta, which owns Krystexxa, a treatment for chronic refractory gout. It's not the first time the med has changed hands recently; in late December, near-bankrupt Savient inked a pact to sell itself and its assets to Crealta for $120.4 million. Release | More

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.